On October 15 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, Howard Hermann, MD, from the University of Pennsylvania presented one-year results from 583 high-risk and inoperable patients treated with Edwards Lifesciences Corp.’s Sapien 3 transcatheter aortic valve using the femoral approach in the PARTNER II trial.
The results showed a survival rate of 89.3% and a 2.4% rate of disabling stroke, and a 2.7% rate of moderate paravalvular leak. No patients showed severe paravalvular leak and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?